Skip to main content

Advertisement

SpringerLink
Log in

Targeting epidermal growth factor receptor in lung cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Among the most promising agents in clinical development to treat non-small-cell lung cancer (NSCLC) are the epidermal growth factor receptor (EGFR) targeting agents. A series of recent studies have demonstrated the activity of anti-EGFR targeted therapies for NSCLC. In advanced NSCLC that is refractory to chemotherapy, antitumor responses have been reported with EGFR tyrosine kinase inhibitors (ZD1839 and OSI-774). The role of ZD1839 and OSI-774 as possible additions to standard chemotherapy in the first-line setting has also been evaluated, and the studies conducted to date should respond to the question of whether these compounds could provide a survival benefit. Other areas of research involve looking at the role of EGFR tyrosine kinase inhibitors in the neoadjuvant treatment of stage III NSCLC and the planning of chemoprevention studies. These exciting results and plans are further complemented by an emerging number of compounds in clinical development, including both monoclonal antibodies (ie, IMC-C225) and other tyrosine kinase inhibitors, directed at the EGFR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lemmon MA, Schlessinger J: Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994, 19:459–463.

    Article  PubMed  CAS  Google Scholar 

  2. Salomon D, Brandt R, Ciardiello F, et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183–232.

    PubMed  CAS  Google Scholar 

  3. Rusch V, Klimstra D, Venkatraman E, et al.: Overexpression of the EGFR and its ligand, TGF alpha, is frequent in resectable non-small cell lung cancer, but does not predict tumor progression. Clin Cancer Res 1997, 3:515–522.

    PubMed  CAS  Google Scholar 

  4. Rusch V, Baselga J, Cordon-Cardo C, et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379–2385.

    PubMed  CAS  Google Scholar 

  5. Rusch V, Klimstra D, Linkov I, et al.: Aberrant expression of p53 or EGFR is frequent in early bronchial preneoplasia and coexpression precedes development of squamous cell carcinoma. Cancer Res 1995, 55:1365–1372.

    PubMed  CAS  Google Scholar 

  6. Lonardo F, Dragnev K, Freemantle S, et al.: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002, 8:54–60.

    PubMed  CAS  Google Scholar 

  7. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Rel Cancer 2001, 8:3–9. This excellent review mainly covers the preclinical and clinical data generated to date with the MAb IMC-C225.

    Article  CAS  Google Scholar 

  8. Baselga J: New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000, 18(suppl):54S-59S.

    PubMed  CAS  Google Scholar 

  9. Baselga J: Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001, 19(suppl):41S-44S. Review of recent clinical evidence of the activity of EGFR targeting agents in studies that are not yet published.

    PubMed  CAS  Google Scholar 

  10. Baselga J, Norton L, Coplan K, et al.: Antitumor activity of pacitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts [abstract]. Proc Am Assoc Cancer Res 1994, 35:2262.

    Google Scholar 

  11. Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904–914.

    PubMed  CAS  Google Scholar 

  12. Shin DM, Donato NJ, Perez-Soler R, et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001, 7:1204–1213.

    PubMed  CAS  Google Scholar 

  13. Albanell J, Codony-Servat J, Rojo F, et al.: Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001, 61:6500–6510.

    PubMed  CAS  Google Scholar 

  14. Bonner JA, Ezequiel MP, Robert F, et al.: Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck carcinoma [abstract]. Proc ASCO 2000, 19:5F.

    Google Scholar 

  15. Rubin MS, Shin DM, Pasmantier M, et al.: Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFR positive tumors refractory to or in relapse from previous therapeutic regimen [abstract]. Proc ASCO 2000, 19:1860.

    Google Scholar 

  16. Hong WK, Arquette M, Nabell L, et al.: Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proc ASCO 2001, 20:224.

    Google Scholar 

  17. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc ASCO 2001, 20:3.

    Google Scholar 

  18. Woodburn J, Kendrew J, Fennell M, et al.: ZD1839 (‘Iressa’) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition [abstract]. Proc Am Assoc Cancer Res 2000, 41:2552.

    Google Scholar 

  19. Moyer JD, Barbacci ES, Iwata KT, et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838–4848.

    PubMed  CAS  Google Scholar 

  20. Slichenmyer WJ, Elliott WL, Fry DW: CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001, 5:80–85.

    Article  Google Scholar 

  21. Bruns CJ, Solorzano CC, Harbison MT, et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60:2926–2935.

    PubMed  CAS  Google Scholar 

  22. Mullin RJ, Alligood KJ, Allen PP, et al.: Anti-tumor activity of GW2016 in the EGFR positive HN5 human head and neck cancer xenograft [abstract]. Proc Am Assoc Cancer Res 2001, 42:854.

    Google Scholar 

  23. Budillon A, Di Gennaro E, Barbarino M, et al.: ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27Kip1 inducing G1 arrest and enhancing the antitumor effect of interferon alpha [abstract]. Proc Amer Assoc Cancer Res 2000, 41:4910.

    Google Scholar 

  24. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063. These authors show the potentiation of chemotherapy activity in human cancer cells by adding an EGFR-TK inhibitor (ZD1839).

    PubMed  CAS  Google Scholar 

  25. Sirotnak FM, Zakowski MF, Miller VA, et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6:4885–4892. These authors show the potentiation of chemotherapy activity in human tumor xenografts by adding an EGFR-TK inhibitor (ZD1839).

    PubMed  CAS  Google Scholar 

  26. Cullinane C, Kleinschimdt M: Antitumour activity of ZD1839 (‘Iressa’) in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor [abstract]. Proc Amer Assoc Cancer Res 2000, 41:3073.

    Google Scholar 

  27. Kelly HC, Laight A, Morris CQ, et al.: Phase I data of ZD1839: an oral epidermal growth factor receptor tyrosine kinase inhibitor [abstract]. Ann Oncol 1998, 2:109.

    Google Scholar 

  28. Baselga J, Herbst R, LoRusso P, et al.: Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract]. Proc ASCO 2000, 19:177.

    Google Scholar 

  29. Goss G, Hirte H, Batist G, et al.: NCIC CTG IND.122: A twopart Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 [abstract]. Proc ASCO 2000, 19:225.

    Google Scholar 

  30. Nakagawa K, Yamamoto N, Kudoh S, et al.: A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours [abstract]. Proc ASCO 2000, 19:183.

    Google Scholar 

  31. Herbst RS, Maddox A-M, Rothenberg ML, et al.: The selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Submitted manuscript.

  32. Baselga J, Rischin D, Ranson M, et al.: Phase I pharmacokinetic and pharmacodynamic trial of ZD1839 (‘Iressa’), a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Submitted manuscript.

  33. Ferry D, Hammond L, Ranson M, et al.: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study [abstract]. Proc ASCO 2000, 19:3.

    Google Scholar 

  34. Albanell J, Rojo F, Baselga J: Pharmacodynamic studies with the EGFR tyrosine kinase inhibitor ZD1839. Semin Oncol 2001 28(suppl 16):56–66.

    Article  PubMed  CAS  Google Scholar 

  35. Albanell J, Rojo F, Averbuch S, et al.: Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 (’Iressa’) in skin from cancer patients: histopathological and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20:110–124. This paper shows that orally administered ZD1839 in cancer patients inhibits EGFR activation and downstream receptor events in the skin, used as a surrogate marker of EGFR targeting, thereby contributing to the selection of optimal biologic doses.

    Article  PubMed  CAS  Google Scholar 

  36. Baselga J, Yano S, Giaccone G, et al.: Initial results from a phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer [abstract]. Proc 12th NCI-AACR-EORTC meeting, 2001:630. Although only presented in abstract form, this study shows the promising antitumor activity of ZD1839 in chemotherapy-refractory NSCLC.

  37. Giaccone G, Gonzales-Larriba J, Smit E, et al.: ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results [abstract]. Eur J Cancer 2001, 37(suppl 6):S30-S31.

    Article  Google Scholar 

  38. Miller V, Johnson D, Heelan R, et al.: A pilot trial demonstrates the safety of ZD1839 (‘Iressa’), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO 2001, 20:326.

    Google Scholar 

  39. Pollack VA, Savage DM, Baker DA, et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291:739–748.

    PubMed  CAS  Google Scholar 

  40. Karp DD, Silberman SL, Csudae R, et al.: Phase I dose escalation study of epidermal growth factor tyrosine kinase inhibitor CP-358,774 in patients with advanced solid tumors [abstract]. Proc ASCO 1999, 18:1499.

    Google Scholar 

  41. Hidalgo M, Siu L, Nemunaitis J, et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267–3279. This elegant phase I study of OSI-774 provides preliminary evidence of its antitumor activity.

    PubMed  CAS  Google Scholar 

  42. Rowinsky EC, Hammond L, Siu L, et al.: Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor [abstract]. Proc ASCO 2001, 20:5A.

    Google Scholar 

  43. Senzer NN, Soulieres D, Siu L, et al.: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [abstract]. Proc ASCO 2001, 20:2.

    Google Scholar 

  44. Finkler N, Gordon A, Crozier M, et al.: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract]. Proc ASCO 2001, 20:208.

    Google Scholar 

  45. Perez-Soler R, Chachoua A, Huberman M, et al.: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO 2001, 20:310. Although only presented in abstract form, this study shows the promising antitumor activity of OSI-774 in chemotherapy-refractory NSCLC.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Service, Hospital General Universitari Vall d’Hebron, Paseo Vall d’Hebron 119-129, 08035, Barcelona, Spain

    José Baselga MD & Joan Albanell MD

Authors
  1. José Baselga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Albanell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baselga, J., Albanell, J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 4, 317–324 (2002). https://doi.org/10.1007/s11912-002-0007-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0007-1

Keywords

Search

Navigation